Cytokinetics reported its financial results for the first quarter of 2017.
Here are five highlights:
1. The company saw revenues of $4.2 million for the first quarter 2017, compared to $8.4 million for the same period in the year prior.
2. Cytokinetics' net loss was $25.9 million, compared to $12.5 million in 2016.
3. The company's cash, cash equivalents and investments were $257.2 million as of March 31, 2017.
4. The company recorded total research and development costs of $19.3 million for the first quarter of 2017.
5. Cytokinetics advanced its muscle biology program, especially with its VITALITY-ALS study. The trial's last patients moved through their primary efficacy endpoint visits in the first quarter of 2017.